Mallinckrodt to Report Earnings Results for Second Quarter 2024
Mallinckrodt plc, a global specialty pharmaceutical company, has announced it will report its second quarter 2024 earnings results on Tuesday, August 6, 2024. The results will cover the period ended June 28, 2024. A conference call for investors is scheduled for 8:30 a.m. ET on the same day. Interested parties can access the call through various means, including:
- Live Call Participant Registration (with dial-in)
- Audio Only Webcast Link (live and replay)
- Mallinckrodt's investor relations website
This announcement provides investors and analysts an opportunity to prepare for the upcoming financial disclosure and engage with the company's management team regarding its performance and outlook.
Mallinckrodt plc, una società farmaceutica specializzata globale, ha annunciato che presenterà i suoi risultati finanziari del secondo trimestre 2024 il martedì 6 agosto 2024. I risultati riguarderanno il periodo concluso il 28 giugno 2024. Una conferenza telefonica per gli investitori è programmata per le 8:30 a.m. ET dello stesso giorno. Le parti interessate possono accedere alla chiamata attraverso vari mezzi, tra cui:
- Registrazione per la partecipazione alla chiamata dal vivo (con numero da chiamare)
- Link per la trasmissione audio in diretta (live e replica)
- Sito web delle relazioni con gli investitori di Mallinckrodt
Questo annuncio offre agli investitori e agli analisti l'opportunità di prepararsi per la prossima divulgazione finanziaria e interagire con il team di gestione dell'azienda riguardo alle sue performance e prospettive.
Mallinckrodt plc, una empresa farmacéutica especializada global, ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 el martes 6 de agosto de 2024. Los resultados cubrirán el período terminado el 28 de junio de 2024. Se ha programado una llamada de conferencia para inversores a las 8:30 a.m. ET el mismo día. Las partes interesadas pueden acceder a la llamada a través de varios medios, incluyendo:
- Registro para la participación en la llamada en vivo (con número de marcado)
- Enlace de transmisión de audio solamente (en vivo y grabación)
- Sitio web de relaciones con inversores de Mallinckrodt
Este anuncio brinda a los inversores y analistas la oportunidad de prepararse para la próxima divulgación financiera y de interactuar con el equipo de gestión de la empresa sobre su desempeño y perspectivas.
Mallinckrodt plc는 글로벌 전문 제약 회사로서 2024년 2분기 실적을 2024년 8월 6일 화요일에 발표할 예정이라고 발표했습니다. 결과는 2024년 6월 28일로 종료된 기간을 다룰 것입니다. 투자자를 위한 컨퍼런스 콜은 같은 날 오전 8시 30분 ET로 예정되어 있습니다. 관심 있는 분들은 다음과 같은 여러 경로를 통해 콜에 참여할 수 있습니다:
- 전화 참여 등록 (다이얼 인 포함)
- 오디오 전용 웹캐스트 링크 (실시간 및 재생)
- Mallinckrodt 투자자 관계 웹사이트
이 발표는 투자자와 분석가에게 다가오는 재무 공시를 준비하고 회사의 성과 및 전망에 대해 경영진과 소통할 수 있는 기회를 제공합니다.
Mallinckrodt plc, une entreprise pharmaceutique spécialisée mondiale, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mardi 6 août 2024. Les résultats couvriront la période se terminant le 28 juin 2024. Une conférence téléphonique pour les investisseurs est prévue le même jour à 8h30 ET. Les parties intéressées peuvent accéder à l'appel par divers moyens, notamment :
- Inscription pour la participation à l'appel en direct (avec numéro de composition)
- Liens de webdiffusion audio uniquement (en direct et en rediffusion)
- Site web des relations avec les investisseurs de Mallinckrodt
Cette annonce offre aux investisseurs et aux analystes l'opportunité de se préparer à la prochaine divulgation financière et d'engager le dialogue avec l'équipe de direction de l'entreprise concernant ses performances et ses perspectives.
Mallinckrodt plc, ein globales Spezialpharmaunternehmen, hat angekündigt, dass es am Dienstag, den 6. August 2024 seine Ergebnisse für das zweite Quartal 2024 bekannt geben wird. Die Ergebnisse betreffen den Zeitraum, der am 28. Juni 2024 endete. Eine Telefonkonferenz für Investoren ist am selben Tag um 8:30 Uhr ET geplant. Interessierte Parteien können über verschiedene Wege auf die Konferenz zugreifen, einschließlich:
- Registrierung für die Teilnahme an der Live-Anruf (mit Einwahlnummer)
- Audio-only-Webcast-Link (live und Wiederholung)
- Mallinckrodt's Investor-Relations-Website
Diese Ankündigung bietet Investoren und Analysten die Möglichkeit, sich auf die bevorstehende finanzielle Offenlegung vorzubereiten und mit dem Managementteam des Unternehmens über die Leistung und Aussichten zu sprechen.
- None.
- None.
A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows:
- Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BI91ab9f1056f04a59a2b623b63c39d8e7
- Audio Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/7aqz6pyp
- At the Mallinckrodt website: https://ir.mallinckrodt.com/
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the
CONTACTS
Investor Relations
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag / Aaron Palash / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-second-quarter-2024-302212388.html
SOURCE Mallinckrodt plc
FAQ
When will Mallinckrodt (MNK) report its Q2 2024 earnings?
What period does Mallinckrodt's (MNK) Q2 2024 earnings report cover?
What time is Mallinckrodt's (MNK) Q2 2024 earnings conference call?
How can investors access Mallinckrodt's (MNK) Q2 2024 earnings call?
